Follicular Lymphoma News and Research

Latest Follicular Lymphoma News and Research

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

ImmunoGen's SAR3419 Phase I trial data on B-cell non-Hodgkin's lymphoma presented at ASCO 2011

Delayed treatment could prove effective in certain medical conditions

Delayed treatment could prove effective in certain medical conditions

Lymphoma vaccine extends disease-free survival by 14 months

Lymphoma vaccine extends disease-free survival by 14 months

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene non-GAAP total revenue increases 40% to $1.11 billion

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

New PTLD Guideline highlighted at NCCN Annual Conference

New PTLD Guideline highlighted at NCCN Annual Conference

CTI announces final pixantrone clinical trial design for treatment of DLBCL

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Researchers to develop computer-assisted diagnosis tools for pathologists

Researchers to develop computer-assisted diagnosis tools for pathologists

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma